Synchrotron diffraction reveals distinct collagen-associated distributions of EGFR-targeted antibody and affibody in pancreatic tumors
Cody C RoundsiD, Sanzida HaqueiD, Chengyue Li, Devin Nissen, Dhruv RanjaniD, Marcella VaicikiD, Rama S. MadhurapantulaiD, Thomas C. IrvingiD, Kenneth M. TichaueriD
Abstract
Significance: Tumor extracellular matrix may influence the distribution of targeted agents differently across molecular formats. We compared how an antibody and an affibody targeting the same receptor distribute relative to collagen associated tissue structure in pancreatic tumors. Methods: Cetuximab IRDye700DX, an epidermal growth factor receptor (EGFR) targeted fluorescent antibody, and ABY029, an EGFR targeted fluorescent affibody, were coadministered intravenously to 12 athymic nude mice bearing orthotopic pancreatic tumors: eight AsPC1 and four PANC1. Tumors were harvested at 3 or 24 h after injection, with four AsPC1 and two PANC1 mice at each time. Fluorescence images from 21 tissue slices were registered to scanning synchrotron X ray diffraction (XRD) maps to compare the distribution of each agent with local collagen associated diffraction intensity. Results: Cetuximab XRD correlations were negative in all 12 mice at every evaluated binning scale (100 to 400 microns, all adjusted P = 0.0039). Cohort average correlations were more negative for cetuximab than ABY029 at all four scales (paired adjusted P = 0.0137 to 0.0381). Conclusions: Cetuximab exhibited consistent inverse spatial associations with collagen-associated diffraction and stronger cohort-average associations than ABY029. These findings show that agents targeting the same receptor can differ in their relationships with local tissue structure and support spatially resolved assessment of tissue access when selecting molecular formats for imaging and therapy.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Extracellular DDR1 targeting remodels collagen-rich tumor stroma and local immunity
Xuan Huang, Xinlin Liu, … Li Ye·bioRxiv·Nov 3, 2026
- Modeling the dynamics of antibody-target binding in living tumors
- Guiding treatment response by spatiotemporal control of α-particle deposition in solid tumors: the case for 'affinity cocktails' of antibody-radioconjugates
Rajiv Ranjit Nair, Aira Sarkar, … Stavroula Sofou·bioRxiv·Dec 25, 2025
- ELIMINATION OF EGFR-OVEREXPRESSING CANCER CELLS BY CD32 CHIMERIC RECEPTOR T CELLS IN COMBINATION WITH CETUXIMAB OR PANITUMUMAB
Sara Caratelli, Roberto Arriga, … Giuseppe Sconocchia·bioRxiv·Mar 18, 2019
- Antitumor activity of a lectibody targeting cancer-associated high-mannose glycans
- A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis